Vaccine Compositions Targeting Pneumococcal Transmission
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines for Streptococcus pneumoniae have limited efficacy at the mucosal surface and fail to effectively address the transmission dynamics of the bacterium, leading to persistent colonization and pneumonia rates due to serotype replacement and incomplete understanding of bacterial and host factors involved in transmission.
Innovation Solution
Development of vaccine compositions containing immunogenic polypeptides from S. pneumoniae proteins involved in transmission, along with methods to identify and manipulate genetic factors affecting transmission, such as reducing proteins involved in desiccation stress tolerance, to block pathogen spread and reduce invasive disease incidence.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pneumococcal conjugate vaccine is introduced, then invasive disease burden is greatly reduced, but colonization and pneumonia rates remain equivalent due to serotype replacement and limited mucosal efficacy
Solution Approach 1:
The vaccine composition is segmented into multiple functional components: a conjugate vaccine component for systemic immunity against invasive disease, and a separate mucosal adjuvant component (such as cytokines IL-17A, IL-22, or TLR agonists) that specifically enhances mucosal surface immunity. This segmentation allows each component to optimize its function independently, addressing both invasive disease protection and mucosal colonization resistance.
Solution Approach 2:
The invention creates a composite vaccine formulation that combines traditional conjugate vaccine antigens (polysaccharide-protein conjugates) with mucosal adjuvants and immunomodulators. This composite approach integrates systemic and mucosal immune activation pathways, producing a multi-functional vaccine that simultaneously addresses invasive disease and mucosal colonization through synergistic immune responses.
2Reliability
If current vaccines target capsular polysaccharides, then serotype-specific protection is achieved, but transmission dynamics are not addressed leading to serotype replacement
Solution Approach 1:
The vaccine composition incorporates universal transmission-blocking components that are not serotype-specific. These include mucosal adjuvants (IL-17A, IL-22, TLR agonists) and anti-virulence factors that target conserved bacterial mechanisms required for transmission across all serotypes. This multi-functionality allows the vaccine to provide both serotype-specific invasive disease protection and broad-spectrum transmission blocking, preventing serotype replacement by addressing the underlying transmission dynamics.
3Loss of information
If single-bacteria transmission model is used, then insights into capsule type and pneumolysin contribution are obtained, but population bottlenecks prevent large scale genetic screens
Solution Approach 1:
The invention introduces an intermediary ferret transmission model that bridges the gap between single-bacteria murine models and human population studies. Ferrets serve as a natural intermediary host that supports large-scale genetic screens while maintaining biologically relevant transmission dynamics. The ferret model allows recovery and sequencing of multiple bacterial genomes from transmitted infections, eliminating population bottlenecks and enabling comprehensive identification of transmission factors across large genetic libraries.
Data Source
AI summary
Compositions and methods are provided for reducing the mammalian transmission of Streptococcus pneumoniae (S. pneumoniae) through the administration to mammalian subjects of vaccine compositions comprising at least one immunogenic polypeptide comprising a S. pneumoniae protein or a fragment or variant thereof that is required for or involved in transmission of the bacteria between mammalian hosts. These vaccine compositions also serve to reduce the incidence rate of at least one invasive disease caused by S. pneumoniae. Methods are also provided for identifying additional genetic factors involved in mammalian transmission of S. pneumoniae.